NCT07379892

Brief Summary

The aim of this study was to evaluate the relationship between Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1), Matrix Metalloproteinases-8 (MMP-8) and Tissue Inhibitors of Metalloproteinases-1 (TIMP-1) levels in peri-implant crevicular fluid (PICF) in peri-implantitis patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2024

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

January 25, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 2, 2026

Completed
Last Updated

February 9, 2026

Status Verified

February 1, 2026

Enrollment Period

7 months

First QC Date

January 25, 2026

Last Update Submit

February 5, 2026

Conditions

Periimplantitis

Keywords

periimplantitisTREM-1MMP-8TIMP-1

Outcome Measures

Primary Outcomes (1)

  • TREM-1, MMP-8 and TIMP-1 levels in PICF samples

    TREM-1, MMP-8, and TIMP-1 levels in PICF samples were measured by ELISA method

    1 month

Study Arms (2)

Peri-implantitis

Peri-implantitis is defined as bleeding on probing, suppuration, increased probing depth, clinical attachment loss, and radiographic bone loss

Other: Collection of PICF samples

Peri-implant Health

Peri-implant health is characterized by the absence of bleeding on probing, erythema, swelling, and suppuration in the peri-implant region

Other: Collection of PICF samples

Interventions

Collection of PICF samplesOTHER

TREM-1, MMP-8 and TIPM-1 levels reseach in PICF samples

Peri-implant HealthPeri-implantitis

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients had at least one implant, and this implant had been in place for at least one year since the implant-supported prosthesis was made.

You may qualify if:

  • Systemically healthy
  • Pregnancy or lactation

You may not qualify if:

  • osteoporosis
  • rheumatoid arthritis
  • autoimmune disease
  • diabetes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aydın Adnan Menderes University

Aydin, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Peri-Implantitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 25, 2026

First Posted

February 2, 2026

Study Start

June 1, 2023

Primary Completion

December 15, 2023

Study Completion

May 20, 2024

Last Updated

February 9, 2026

Record last verified: 2026-02

Locations

TU(1)